MS417 manufacturers
- MS417
-
- $64.00 / 5mg
-
2025-11-10
- CAS:916489-36-6
- Min. Order:
- Purity: 99.87%
- Supply Ability: 10g
|
| Product Name: | MS417 | | Synonyms: | MS417;(S)-methyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate;MS-417; M S417;GTPL7512;6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid, 4-(4-chlorophenyl)-2,3,9-trimethyl-, methyl ester, (6S)-;Epigenetic Reader Domain,inhibit,MS417,HIV,MS 417,GTPL 7512,Inhibitor,MS-417,GTPL-7512,Human immunodeficiency virus;methyl(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate;MS147 | | CAS: | 916489-36-6 | | MF: | C20H19ClN4O2S | | MW: | 414.91 | | EINECS: | | | Product Categories: | | | Mol File: | 916489-36-6.mol |  |
| | MS417 Chemical Properties |
| Boiling point | 596.8±60.0 °C(Predicted) | | density | 1.43±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Ethanol : 50 mg/mL (120.51 mM) | | form | Solid | | pka | 1.86±0.60(Predicted) | | color | Light yellow to yellow |
| | MS417 Usage And Synthesis |
| Uses | MS417 is a selective BET-specific BRD4 inhibitor, binds to BRD4-BD1 and BRD4-BD2 with IC50s of 30, 46 nM and Kds of 36.1, 25.4 nM, respectively, with weak selectivity at CBP BRD (IC50, 32.7 μM). | | Definition | ChEBI: MS-417 is a member of the class of thienotriazolodiazepines that is the methyl ester of [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetic acid. A bromodomain and extra-terminal domain (BET)-specific inhibitor that belongs to a group of thienodiazepine-based compounds It is a thienotriazolodiazepine, a member of monochlorobenzenes and a methyl ester. It is an enantiomer of a MS-566. | | Biological Activity | MS417, a (+)-JQ1 analog, is a potent inhibitor of bromodomain-containing protein 4 (BRD4) th at is highly specific for BRD4-BD1 and BRD4-BD2. MS417 binds with similar affinity to BRD4-BD1 and BRD4-BD2 (Kd =36.1, and 25.4 nM), while bulky tBu of JQ1 prevents tight binding to the cavity at BD1. | | in vivo | MS417 (0.08 mg/kg) markedly improves renal function, reduces proteinuria and decreases glomerulosclerosis, tubular injury, and infiltration of inflammatory cells in the kidney of Tg26 mice[1]. | | References | [1] Zhang G, et al. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012 Aug 17;287(34):28840-51. DOI:10.1074/jbc.M112.359505 |
| | MS417 Preparation Products And Raw materials |
|